Claudio Stadnik

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19

Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez et al. · JAMA · 2022 · 294 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +12

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

Ildikó Madurka, Alexander Vishnevsky, Joan B. Soriano et al. · Infection · 2022 · 83 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia

Jane A. O’Halloran, Emily R. Ko, Kevin J. Anstrom et al. · JAMA · 2023 · 67 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +11

Carbapenemase-Producing Klebsiella pneumoniae From Transplanted Patients in Brazil: Phylogeny, Resistome, Virulome and Mobile Genetic Elements Harboring blaKPC–2 or blaNDM–1

Otávio Hallal Ferreira Raro, Ravena Maya Cardoso da Silva, Édison Moraes Rodrigues Filho et al. · Frontiers in Microbiology · 2020 · 30 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial

Suzana Margareth Lobo, Gaëtan Plantefève, Girish B. Nair et al. · EClinicalMedicine · 2024 · 27 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16